Literature DB >> 1905050

A national survey of state maternal and newborn drug testing and reporting policies.

T A Adirim1, N Sen Gupta.   

Abstract

The prevalence rate of drug use by pregnant women in the United States has been shown to range from 7.5 percent to 11 percent. Drug exposure in utero has been associated with deleterious effects on the fetus and newborn. Public health officials are currently confronted with difficult policy decisions with regard to testing and reporting of pregnant and post-partum women and the provision of appropriate services. The widespread lack of consistent policy on the State level has led to bias in testing and reporting procedures and to the inappropriate use of the legal system as a deterrent to drug use during pregnancy. A survey of the 50 States and the District of Columbia found that no State currently has enacted legislation regarding testing. Thirteen States have mandatory reporting policies for drug-exposed newborns. Eleven of these States require reporting to social service agencies, at least 3 States routinely report to criminal justice agencies, and 10 require that reports be filed as child abuse or neglect. Many States without mandatory reporting statutes indicate that reports are made to social service agencies at the discretion of the health care provider. During fiscal year 1990, only 22 States specifically allocated funds for programs that address perinatal substance use. In States with mandatory reporting policies, reports should be made only to social service agencies in conjunction with the provision of appropriate preventive, medical, and social services to the woman and her infant. Interagency coordination is necessary to standardize testing and reporting practices within States and to effectively allocate resources.

Entities:  

Mesh:

Year:  1991        PMID: 1905050      PMCID: PMC1580248     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  12 in total

1.  Effects of maternal marijuana and cocaine use on fetal growth.

Authors:  B Zuckerman; D A Frank; R Hingson; H Amaro; S M Levenson; H Kayne; S Parker; R Vinci; K Aboagye; L E Fried
Journal:  N Engl J Med       Date:  1989-03-23       Impact factor: 91.245

2.  Drug use and women: establishing a standard of care.

Authors:  I J Chasnoff
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

3.  Effect of cocaine on uterine blood flow and fetal oxygenation.

Authors:  J R Woods; M A Plessinger; K E Clark
Journal:  JAMA       Date:  1987-02-20       Impact factor: 56.272

4.  Prenatal opioid exposure and the problem of causal inference.

Authors:  D E Hutchings
Journal:  NIDA Res Monogr       Date:  1985

5.  Prenatal drug exposure: effects on neonatal and infant growth and development.

Authors:  I J Chasnoff; K A Burns; W J Burns; S H Schnoll
Journal:  Neurobehav Toxicol Teratol       Date:  1986 Jul-Aug

6.  Cocaine abuse in pregnancy: effects on the fetus and newborn.

Authors:  L Ryan; S Ehrlich; L Finnegan
Journal:  Neurotoxicol Teratol       Date:  1987 Jul-Aug       Impact factor: 3.763

7.  Cocaine use during pregnancy: adverse perinatal outcome.

Authors:  S N MacGregor; L G Keith; I J Chasnoff; M A Rosner; G M Chisum; P Shaw; J P Minogue
Journal:  Am J Obstet Gynecol       Date:  1987-09       Impact factor: 8.661

8.  The effect of cocaine abuse on birth weight and gestational age.

Authors:  M Chouteau; P B Namerow; P Leppert
Journal:  Obstet Gynecol       Date:  1988-09       Impact factor: 7.661

9.  Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies.

Authors:  G F Chávez; J Mulinare; J F Cordero
Journal:  JAMA       Date:  1989-08-11       Impact factor: 56.272

10.  A cohort study of alkaloidal cocaine ("crack") in pregnancy.

Authors:  R Cherukuri; H Minkoff; J Feldman; A Parekh; L Glass
Journal:  Obstet Gynecol       Date:  1988-08       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.